Charles is a force to be reckoned with in the world of print and new media. From an interview with him in LowEndMac: ”His articles, features, and commentaries have appeared in more than 40 magazines, newspapers and websites in Canada, the US, the UK, and Australia. . . a columnist for The Halifax Daily News and the Saint John Telegraph Journal, Atlantic Fisherman, and news editor and columnist for Applelinks.com, a columnist and contributing editor for MacOpinion and PBCentral, as well as writing for Low End Mac.” Charles serves as the Senior Section Editor for the Science and Research section of BioNews Texas and contributes science-related articles on a daily basis.
Jiffy Lube and the Muscular Dystrophy Association (MDA) are teaming up again this summer for the 6th annual MUSCLE UP! campaign. Each August for the past five years, Jiffy ... Read more
The Stephen J. Wampler Foundation has reached an agreement to purchase a new home for Camp Wamp, an outdoor wilderness adventure camp for children with physical disabilities. Previously a Girl ... Read more
Andrea Dalzell, Ms. Wheelchair New York 2015, is featured among the disability advocates who will appear at the United Spinal Association’s 6th Annual Roll on Capitol Hill. Advocates will speak ... Read more
CureDuchenne has announced its enthusiastic support and sponsorship of California Senate bill SB 643, which adds Duchenne muscular dystrophy to California’s Genetically Handicapped Persons Program (GHPP) list of eligible medical conditions. The ... Read more
The nonprofit Duchenne muscular dystrophy (DMD) research and advocacy organization Parent Project Muscular Dystrophy (PPMD) awarded a $2.2 million grant to Jerry Mendell, MD, PhD; co-principal investigator Louise Rodino-Klapac, PhD; ... Read more
The study of rare diseases is typically short-changed with research funding, and the creation and sharing of tools to fight these disorders is the mission of a new initiative ... Read more
CureDuchenne Ventures is investing in Therapeutic Research in Neuromuscular Disorders Solutions (TRiNDS), a new specialized contract research organization. TRiNDS is hived off from the Cooperative International Neuromuscular Research Group (CINRG), an ... Read more
At Catabasis Pharmaceuticals’ first Investor Day earlier this month, the company provided an in-depth review of its strategy and development pipeline of product candidates for treating rare diseases, including the Duchenne ... Read more
Nonprofit organizations CureDuchenne and Art In Giving are co-hosting a “Dealing for Duchenne” charity event in Cambridge, Massachusetts, on Oct. 20 to support the quest for a Duchenne muscular ... Read more
Summit Therapeutics announced that it has received a Rare Pediatric Disease designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate, ezutromid, as a treatment for ... Read more
